 |
Breakthrough by NYCU and TYGH: Febuxostat Shows Dual Benefits for CKD Patients |
Patients with chronic kidney disease (CKD) often experience the accumulation of uremic toxins, which increases oxidative stress and inflammation, subsequently leading to cardiovascular diseases. A research team from TYGH, Ministry of Health and Welfare, and NYCU has discovered that Febuxostat, a drug ...
|
|